Marshall Financial Group LLC Decreases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Marshall Financial Group LLC decreased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 80.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 960 shares of the pharmaceutical company's stock after selling 3,963 shares during the quarter. Marshall Financial Group LLC's holdings in Vertex Pharmaceuticals were worth $387,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Linden Thomas Advisory Services LLC increased its stake in shares of Vertex Pharmaceuticals by 9.5% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 7,441 shares of the pharmaceutical company's stock worth $2,996,000 after acquiring an additional 644 shares during the period. Pflug Koory LLC increased its stake in shares of Vertex Pharmaceuticals by 4.1% in the fourth quarter. Pflug Koory LLC now owns 2,018 shares of the pharmaceutical company's stock worth $813,000 after acquiring an additional 79 shares during the period. Goelzer Investment Management Inc. grew its position in Vertex Pharmaceuticals by 1.5% during the fourth quarter. Goelzer Investment Management Inc. now owns 1,915 shares of the pharmaceutical company's stock valued at $771,000 after buying an additional 29 shares during the period. Brighton Jones LLC grew its position in Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock valued at $1,783,000 after buying an additional 579 shares during the period. Finally, Montecito Bank & Trust grew its position in Vertex Pharmaceuticals by 2.5% during the fourth quarter. Montecito Bank & Trust now owns 1,659 shares of the pharmaceutical company's stock valued at $668,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Trading Up 1.0 %

Vertex Pharmaceuticals stock traded up $4.26 during midday trading on Monday, hitting $443.88. 1,612,847 shares of the stock were exchanged, compared to its average volume of 1,546,018. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The stock has a market capitalization of $114.31 billion, a price-to-earnings ratio of -223.06, a PEG ratio of 2.20 and a beta of 0.40. The stock's 50-day simple moving average is $435.36 and its 200 day simple moving average is $464.32. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.69 billion. During the same period last year, the business earned $3.67 earnings per share. The business's revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Piper Sandler dropped their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a research report on Monday. StockNews.com lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Finally, BMO Capital Markets decreased their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a report on Friday, December 20th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $494.76.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.